5-Benzothiazole substituted pyrimidine derivatives as HCV replication (replicase) inhibitors

Add time:09/25/2019    Source:sciencedirect.com

Based on a previously identified HCV replication (replicase) inhibitor 1, SAR efforts were conducted around the pyrimidine core to improve the potency and pharmacokinetic profile of the inhibitors. A benzothiazole moiety was found to be the optimal substituent at the pyrimidine 5-position. Due to potential reactivity concern, the 4-chloro residue was replaced by a methyl group with some loss in potency and enhanced rat in vivo profile. Extensive investigations at the C-2 position resulted in identification of compound 16 that demonstrated very good replicon potency, selectivity and rodent plasma/target organ concentration. Inhibitor 16 also demonstrated good plasma levels and oral bioavailability in dogs, while monkey exposure was rather low. Chemistry optimization towards a practical route to install the benzothiazole moiety resulted in an efficient direct C–H arylation protocol.

We also recommend Trading Suppliers and Manufacturers of 4-IODO-2-(METHYLTHIO)PYRIMIDINE (cas 1122-74-3). Pls Click Website Link as below: cas 1122-74-3 suppliers

Prev:Chapter One - Recent advances in 1,2,4-triazolo[1,5-a]pyrimidine chemistry☆
Next:A concise Pd catalyzed cross coupling reaction along with deprotection for the synthesis of a new series of pyrimidine derivatives)